Evidence map›Paper›PMID 30360354›Full record

ArticleBiomedicines2018

Azasulfurylpeptide Modulation of CD36-Mediated Inflammation Without Effect on Neovascularization.

Stéphane Turcotte, Katia Mellal, Ramesh Chingle, Mukandila Mulumba, Samy Omri, Lylia Dif-Yaiche, Sylvain Chemtob, Huy Ong, William D Lubell

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomedicines, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.5field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 5 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Stéphane TurcotteDepartments of Chemistry, Université de Montréal, Montréal, QC H3C 3J7, Canada. stephane.turcotte@intellisynrd.com.ORCID 0000-0002-8356-5503
Katia MellalFaculty of Pharmacy, Université de Montréal, Montréal, QC H3C 3J7, Canada. katia.mellal@gmail.com.
Ramesh ChingleDepartments of Chemistry, Université de Montréal, Montréal, QC H3C 3J7, Canada. rameshchingle26@gmail.com.ORCID 0000-0003-1175-2454
Mukandila MulumbaFaculty of Pharmacy, Université de Montréal, Montréal, QC H3C 3J7, Canada. dilan.mulumba@gmail.com.ORCID 0000-0001-7708-7480
Samy OmriMaisonneuve-Rosemont Hospital, Montréal, QC H1T 2M4, Canada. samy.omri@gmail.com.
Lylia Dif-YaicheDepartments of Chemistry, Université de Montréal, Montréal, QC H3C 3J7, Canada. dif.yaiche.lylia@gmail.com.
Sylvain ChemtobMaisonneuve-Rosemont Hospital, Montréal, QC H1T 2M4, Canada. sylvain.chemtob@gmail.com.
Huy OngFaculty of Pharmacy, Université de Montréal, Montréal, QC H3C 3J7, Canada. huy.ong@umontreal.ca.
William D LubellDepartments of Chemistry, Université de Montréal, Montréal, QC H3C 3J7, Canada. william.lubell@umontreal.ca.
Université de Montréal · CAHôpital Maisonneuve-Rosemont · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Modulation of the cluster of differentiation-36 receptor (CD36) has proven promising for dampening pro-inflammatory macrophage signaling. For example, azapeptides (e.g.,

Indexed as

age-related macular degenerationazapeptideazasulfurylpeptidecluster of differentiation 36fibroblast-stimulating lipopeptidegrowth hormone-releasing peptide-6N-Aminosulfamidenitric oxidesemicarbazidetoll-like receptortumor necrosis factor-α

Identifiers

PMID30360354
PMCPMC6315388
OpenAlexW2896079329

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.